Abstract | PURPOSE: EXPERIMENTAL DESIGN: A case-control study was performed including 500 patients with histologically confirmed breast cancer and 500 female, age-matched, healthy control subjects from population-based screening studies. The MMP3 5A/6A polymorphism was determined by a 5'-nuclease (TaqMan) assay. RESULTS: Prevalences of 5A/5A, 5A/6A, and 6A/6A genotypes were similar among patients (20.6, 51.8, and 27.6%, respectively) and controls (23.3, 47.3, and 29.4%, P = 0.34). The odds ratio of carriers of a MMP3 5A allele for breast cancer was 1.09 (95% confidence interval, 0.83-1.44). Patients with the 5A/5A genotype had a higher proportion of lymph-node metastases than those with a 5A/6A or 6A/6A genotype (P = 0.010). CONCLUSIONS: The MMP3 5A/6A promoter polymorphism does not appear to influence breast cancer susceptibility but may be linked to a higher risk for metastasizing among breast cancer patients.
|
Authors | Peter Krippl, Uwe Langsenlehner, Wilfried Renner, Babak Yazdani-Biuki, Herwig Köppel, Andreas Leithner, Thomas C Wascher, Bernhard Paulweber, Hellmut Samonigg |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 10
Issue 10
Pg. 3518-20
(May 15 2004)
ISSN: 1078-0432 [Print] United States |
PMID | 15161710
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Matrix Metalloproteinase 3
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Alleles
- Breast Neoplasms
(genetics)
- Case-Control Studies
- Female
- Genetic Predisposition to Disease
- Genotype
- Humans
- Lymphatic Metastasis
- Matrix Metalloproteinase 3
(genetics)
- Middle Aged
- Models, Genetic
- Odds Ratio
- Polymorphism, Genetic
- Promoter Regions, Genetic
|